[1] Dasgupta T, Wilson LD, Yu JB. A retrospective review of 1349 cases of sebaceous carcinoma. Cancer. 2009;115(1):158-65. https://doi.org/10.1002/cncr.23952.
[2] Tripathi R, Chen Z, Li L, Bordeaux JS. Incidence and survival of sebaceous carcinoma in the United States. Journal of the American Academy of Dermatology. 2016;75(6):1210-5. https://doi.org/10.1016/j.jaad.2016.07.046.
[3] Sa HS, Rubin ML, Xu S, Ning J, Tetzlaff M, Sagiv O, et al. Prognostic factors for local recurrence, metastasis and survival for sebaceous carcinoma of the eyelid: observations in 100 patients. British Journal of Ophthalmology. 2019;103(7):980-4. https://doi.org/10.1136/bjophthalmol-2018-312635.
[4] Papadimitriou I, Vakirlis E, Sotiriou E, Bakirtzi K, Lallas A, Ioannides D. Sebaceous neoplasms. Diagnostics. 2023;13(10):1676. https://doi.org/10.3390/diagnostics13101676.
[5] Pleitz JL, Patel AB, Spires SE, Anderson FL, Aouad RK. A mass on the nasal dorsum. JAMA Otolaryngology–Head & Neck Surgery. 2014;140(3):267-8.
[6] Kyllo RL, Brady KL, Hurst EA. Sebaceous carcinoma: review of the literature. Dermatologic Surgery. 2015;41(1):1-15. https://doi.org/10.1097/DSS.0000000000000152.
[7] Cook S, Pethick J, Kibbi N, Hollestein L, Lavelle K, de Vere Hunt I, et al. Sebaceous carcinoma epidemiology, associated malignancies and Lynch/Muir-Torre syndrome screening in England from 2008 to 2018. Journal of the American Academy of Dermatology. 2023;89(6):1129-35. https://doi.org/10.1016/j.jaad.2023.03.046.
[8] Elston DM. Sebaceous neoplasms and the Muir-Torre syndrome. Journal of the American Academy of Dermatology. 2023;89(6):1123. https://doi.org/10.1016/j.jaad.2023.05.012.
[9] Hata M, Koike I, Omura M, Maegawa J, Ogino I, Inoue T. Noninvasive and curative radiation therapy for sebaceous carcinoma of the eyelid. International Journal of Radiation Oncology* Biology* Physics. 2012;82(2):605-11. https://doi.org/10.1016/j.ijrobp.2010.12.006.